After Ignoring Letters From US FDA, Teva And Cipla Will Have ANDAs Withdrawn

 
• By Brenda Sandburg

Watson (now Teva) and InvaGen (now Cipla) failed to submit new bioequivalence data following enforcement action against Cetero Research.

Building icon with inscription FDA and flag of The United States over abstract background. - Illustration

More from US FDA

More from Agency Leadership